1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. ALKEM LABORATORIES LTD.
Alkem Laboratories Ltd.
NSE: ALKEM | BSE: 539523

Alkem Laboratories Live Share Price Today, Share Analysis and Chart

Mid-range Performer
BasketIn 1 Starfolio Basket
aboutAlkem Laboratories Ltd. is the fifth-largest pharmaceutical company in India, with a presence spanning over 50 years. The company operates across the pharmaceutical value chain, including research, development, manufacturing, and marketing of... Read More
Ask AI about Alkem Laboratories
5113.5034.50(0.68%)

52W Low on Oct 22, 2026

109.1K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
41.2 / 100
Mid-range PerformerThese stocks have average quality, financial and technical momentum, indicating a mid range performerView SimilarEmbed DVM
Analyst Price Target
-

14

S

6

W

5

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

11Positive12Negative

47.8%Pass in checklist

045
55
100

PE Valuation Check

Right Now
Undervalued
18.8%
1 Year Forward
Undervalued
25.4%
INSIGHTAlkem Laboratories is undervalued at both current PE and future earnings estimates.

Alkem Laboratories Stock Price Analysis

Day Price Range

0.7% 1 Day return
5113.5 (LTP)
5,0305,134.5
LowHigh

Week Price Range

3.4% 1 Week return
5113.5 (LTP)
4,878.55,166
LowHigh

Month Price Range

-2.6% 1 Month return
5113.5 (LTP)
4,8115,407
LowHigh

52 Week Price Range

-7.4% 1 Year return
5113.5 (LTP)
4,8115,933.5
LowHigh
View full Price History/Seasonality

Alkem Laboratories Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Alkem Laboratories's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
192.5
AVG. ESTIMATE
192
LOW ESTIMATE
180
HIGH ESTIMATE
234.1
CURRENT EPS
AVG. ESTIMATE
Miss

EPS is expected to reduce by 0.3% in FY27

Consensus Recommendation

20 ANALYST Recommendations
BUY

The consensus recommendation from 20 analysts for Alkem Laboratories is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Alkem Laboratories Technical Analysis

Alkem Laboratories EMA & SMA

Bearish-2
3 bullish, 5 bearish
Bullish3
Bearish5
5 Day5077.7
10 Day5080.5
12 Day5087.8
20 Day5121.4
26 Day5145.3
50 Day5223.9
100 Day5315.7
200 Day5374.8

Alkem Laboratories Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202658.5%
Week49.9%
Month63.1%

Alkem Laboratories Active Candlesticks

Engulfing Uptrend Long Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Alkem Laboratories Resistance and Support

5092.67
Pivot
First Resistance5155.3
Second Resistance5197.2
Third Resistance5259.8
First Support5050.8
Second Support4988.2
Third Support4946.3
Day RSI47.2
Day MACD-57.5
Day MFI36.3
Day MACD Signal Line-62

Alkem Laboratories Beta

1 Month0.4
1 Year0.7
3 Month0.5
3 Year0.6

Alkem Laboratories Price Change Analysis

↓-2.6%
Over 1 Month
LowHigh
48115407
↓-12.1%
Over 3 Months
LowHigh
48115833
↓-4.3%
Over 6 Months
LowHigh
48115882.5
↓-7.5%
Over 1 Year
LowHigh
48115933.5
All Technicals →

Alkem Laboratories Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Sarandhar Singh * (Please Refer Notes)Promoter21,864,08818.3 %
Kishor Kumar SinghPublic2,973,3122.5 %
Hdfc Mutual Fund - Hdfc Mid-Cap FundDii6,391,8915.4 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Alkem Laboratories Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
SAMPRADA&NANHAMATI SINGH FAMILY TRUSTBlockSell02 Jun 20265200550,000NSE
JAYANTI SINHABlockSell02 Jun 202652001,238,220NSE
EDELWEISS MUTUAL FUNDBlockPurchase02 Jun 2026520048,090NSE
GOLDMAN SACHS BANK EUROPE SEBlockPurchase02 Jun 2026520048,090NSE
HDFC MUTUAL FUNDBlockPurchase02 Jun 20265200509,615NSE
ICICI PRUDENTIAL MUTUAL FUNDBlockPurchase02 Jun 20265200903,527NSE
MORGAN STANLEY ASIA SINGAPORE PTEBlockPurchase02 Jun 2026520048,090NSE
NIPPON INDIA MUTUAL FUNDBlockPurchase02 Jun 2026520048,090NSE
SOCIETE GENERALEBlockPurchase02 Jun 2026520048,090NSE
DSP MUTUAL FUNDBlockPurchase02 Jun 2026520086,538NSE
All deals
All insider trades

Alkem Laboratories Corporate Actions

Alkem Laboratories Dividend history and yield

Alkem Laboratories dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Alkem Laboratories dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
107 Aug 2026
10FINAL07 Aug 2026Equity Share
220 Feb 2026
43INTERIM20 Feb 2026Equity Share
308 Aug 2025
8FINAL08 Aug 2025Equity Share
414 Feb 2025
37INTERIM14 Feb 2025Equity Share
509 Aug 2024
5FINAL10 Aug 2024Equity Share

Alkem Laboratories Board Meetings

Alkem Laboratories past and upcoming board meetings.

#Ex-Date
PurposeNotes
114 Aug 2026
Quarterly Results-
228 May 2026
Audited Results & Final Dividend-
313 Feb 2026
Quarterly Results & Interim Dividend-
413 Nov 2025
Quarterly Results-
512 Aug 2025
Quarterly Results-
All Corporate Actions

Alkem Laboratories Research Reports

Alkem Laboratories research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
114 Aug 2026Motilal Oswal57705368Neutral7.49%-4.74%pdf
213 Aug 2026BOB Capital Markets Ltd.45905368Sell-14.49%-4.74%pdf
328 May 2026BOB Capital Markets Ltd.
Reco
Target
46385498Sell-15.64%-6.99%pdf
427 May 2026ICICI Securities Limited
Target
68505451.5Buy25.65%-6.2%pdf
527 May 2026Motilal Oswal
Target
58405451.5Neutral7.13%-6.2%pdf
All Reports of Alkem

Alkem Laboratories Corporate Filings

Alkem Laboratories BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
30 Oct 2026
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Update On US FDA Inspection At Company's API manufacturing facility located at Mandva.
PDF
21 Oct 2026
Alkem Laboratories Ltd - 539523 - Announcement Under Regulation 30 (LODR)- Intimation Regarding Initiation Of Forensic Audit
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III thereto, we wish to inform you that the Audit Committee at its meeting today, i.e. 21st October, 2026, has approved the initiation of forensic audit in connection with a recent incident involving alleged misappropriation of funds by a former employee of the Company, for examining the facts and circumstances relating to the incident, determining the root cause and recommending appropriate corrective measures.
PDF
12 Oct 2026
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Change in Management
Please find attached herewith intimation for appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnels of the Company.
PDF
24 Sep 2026
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Cessation
Please find attached herewith intimation for change in Key Managerial Personnel - Resignation of Chief Financial Officer
PDF
23 Sep 2026
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find attached herewith intimation of Schedule of Analyst / Institutional Investor Meeting.
PDF
VIEW ALL

Alkem Laboratories DocumentsAsk MarketMind AI

Alkem Laboratories Earnings Call

Alkem Laboratories earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
20 Aug 2026Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
20 Aug 2026Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
14 Aug 2026Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
14 Aug 2026Alkem Laboratories Results Earnings Call for Q1FY27AudioVideo
01 Jun 2026Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Alkem Laboratories Annual Reports

Alkem Laboratories financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2022Annual Report Mar-2022Link
2021Annual Report Mar-2021Link

Alkem Laboratories Credit Ratings

Alkem Laboratories credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
07 Jul 2026crisil ratingsAlkem Laboratories LimitedAlkem Laboratories Limited:Ratings reaffirmed at 'Crisil AA+ / Stable / Crisil A1+ '; Rated amount enhanced for Bank DebtLink
23 Feb 2026crisil ratingsAlkem Laboratories LimitedAlkem Laboratories Limited:Ratings reaffirmed at 'Crisil AA+/Stable/Crisil A1+'Link
05 Feb 2026india ratingsIndia Ratings Affirms Alkem Laboratories’s CP at ‘IND A1+'Link
04 Jan 2026care ratingsAlkem Laboratories LimitedLink
14 Sep 2025crisil ratingsAlkem Laboratories LimitedAlkem Laboratories Limited:Ratings reaffirmed at 'Crisil AA+/Stable/Crisil A1+'Link

Alkem Laboratories Investor Presentations

Alkem Laboratories investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
14 Aug 2026Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
28 May 2026Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
18 Feb 2026Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
16 Feb 2026Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
13 Feb 2026Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Alkem Laboratories - Company Profile

Alkem Laboratories Management Structure

Alkem Laboratories management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Sujit ShettySenior Vice President(Internal Audit)-Mar 26
Ms. Charu AryaAssistant Vice President(Marketing,Sales)-Mar 26
Mr. Ashish Kumar SureshAssistant Vice President,Head(Middle East Region)-Mar 26
Mr. Shamsher Kumar DeoVice President(Sales & Marketing)-Mar 26
Mr. Sunil SawantVice President(Global Distribution,Supply Chain.)-Mar 26
Mr. Sanjay Kumar DipakVice President(Sales & Marketing)-Mar 26
Mr. Ramanarayana ParhiVice President,Chief Information Officer-Mar 26
Mr. Abhijit BasakVice President(Corporate Strategy,Business Development)-Mar 26
Mr. Prakash RamnaniSenior Vice President.(Formulations,Operations,Manufacturing)-Mar 26
Mr. Vishal MeswaniSenior Vice President(Marketing,Sales)-Mar 26
Dr. Jitendra Singh HudaSenior Vice President(Marketing,Sales)-Mar 26
Mr. V. Hari KrishnaSenior Vice President(Marketing,Sales)-Mar 26
DIVYA HARILAL MEWANIVice President(Legal.),Deputy Company Secretary-Mar 26
Mr. Shirish Purushotham AmbulgekarPresident,Head(Global Quality)-Mar 26
Mr. Ashish SehgalPresident(Formulations,R&D Services,Regulatory Affairs)-Mar 26
Dr. Akhilesh SharmaPresident,Chief Medical Officer-Mar 26
Mr. Sunil Kumar PathakPresident(Sales & Marketing)-Mar 26
Mr. Rajorshi GanguliPresident,Global Head(HR)-Mar 26
Mr. Aniruddha SinghAssistant General Manager(CMD)-Mar 26
Mr. Sarandhar SinghVice President(Sales & Marketing)-Mar 26
Mr. Satish Kumar SinghHead(Operations)-Mar 26
Manish NarangPresident(Legal.),Company Secretary,Compliance Officer-Mar 26
Mr. Nitin AgrawalPresident,Chief Financial Officer-Mar 26

Alkem Laboratories Board of Directors

Alkem Laboratories Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Basudeo N SinghChairman/ED & CEO2170Mar 26
Mritunjay Kumar SinghExecutive Director1131Mar 26
Madhurima SinghExecutive Director1115Mar 26
Srinivas SinghExecutive Director1072Mar 26
SANDEEP SINGHED / MD / Promoter789Mar 26
SARVESH SINGHExecutive Director454Mar 26
Narendra AnejaIndependent Non Exe. Director34Mar 26
Sujjain TalwarIndependent Non Exe. Director30.5Mar 26
Rajeev KherIndependent Non Exe. Director23.2Mar 26
R L ShenoyIndependent Non Exe. Director5.5Mar 26
Diwakar GuptaIndependent Non Exe. Director5.5Mar 26
Neela BhattacherjeeIndependent Non Exe. Director2.5Mar 26
Manish NarangPresident / Company Secretary / Compliance Officer-Mar 26

Alkem Laboratories Brands

Brands owned by Alkem Laboratories

LOGOBRAND NAME
A to Z drop
Euclide 80
A to Z NS
A to Z Women
LOGOBRAND NAME
Jupiros-F
Lamokem OD
Levenue
Lilituf
LOGOBRAND NAME
Saftoin
Satrogyl
SIZLAC
SUMO COLD PCF
LOGOBRAND NAME
BORTEPLUS
BRETOLAP
CAPETA NOVA
CARBOKEM NOVA
Website: www.alkemlabs.com

About the company - Business Profile

Alkem Laboratories Ltd. is the fifth-largest pharmaceutical company in India, with a presence spanning over 50 years. The company operates across the pharmaceutical value chain, including research, development, manufacturing, and marketing of branded generics, complex generics, biosimilars, and nutraceuticals. It holds a dominant market position in acute therapy areas, particularly in anti-infectives, where it has maintained leadership for over 15 years.

Key Points

  • Key Facts:
    • Founded: Established over 50 years ago.
    • Headquarters: Mumbai, India.
    • Stock Listing: Listed on BSE (539523) and NSE (ALKEM).
    • Promoter Holding: 51.2% (as of December 31, 2025).
    • Market Position: 5th largest in India by value; 3rd in prescriptions (IQVIA MAT March 2025).
  • Operations and Resources:
    • Manufacturing Facilities: Operates 18 manufacturing sites across India and the US, including 6 USFDA-approved facilities located in Baddi, Daman, Ankleshwar, Mandva (India), and California (USA).
    • R&D Infrastructure: Houses 3 R&D centres (some documents mention a 4th centre) focusing on formulations, APIs, and biosimilars. The Taloja R&D centre (Bioequivalence Centre) received no observations during its April 2025 inspection.
    • Distribution Network: Supported by over 8,800 stockists, 77 depots and CFAs, and a field force exceeding 12,500 medical representatives.
  • Business Model and Market Significance:
    • The company follows a branded generics model in India and a generic formulations model in the US and other international markets.
    • It is a leader in Acute Therapies: #1 in Anti-infectives, #2 in Vitamins/Minerals/Nutrients (VMN), and #3 in Gastrointestinal and Pain Management.
    • Chronic Therapies: Actively scaling in Neuro/CNS, Anti-diabetes, Dermatology, and Respiratory segments. The Anti-diabetic segment outperformed Indian Pharmaceutical Market (IPM) growth by 1.14x in FY2025.
  • Revenue Breakdown (FY2025):
    • Total Revenue: ₹1,29,645 million.
    • Geographical Split:
      • India: ₹89,837 million (70.2%).
      • United States: ₹24,818 million (19.4%).
      • Other International: ₹13,392 million (10.4%).
  • Key Products and Technology:
    • Flagship Brands: Clavam, Pan, Pan-D, and Taxim-O are ranked among the Top 50 brands in the Indian pharmaceutical market.
    • Product Filings: As of December 31, 2025, Alkem has filed 188 ANDAs, 2 NDAs, and 1 BLA with the USFDA, securing 167 ANDA approvals (including 20 tentative).
    • Subsidiaries: Includes Enzene Biosciences (focused on biosimilars and CDMO), Ascend Laboratories (US/international), and Pharmacor. Enzene is expanding into the US market with a new manufacturing plant.
  • Strategic Initiatives and Outlook:
    • Expansion: Strengthening the CDMO business through Enzene and diversifying into chronic therapies to balance the acute-heavy portfolio.
    • Sustainability: Focus on ESG with a goal of sustainable profitability and adherence to EHS standards.
    • Digital Transformation: Implementing digital initiatives to enhance operational efficiency and market reach.
  • Employee Information:
    • Employs over 21,000 people globally with a field force of approximately 12,500.

References

  1. Annual Report May 2025
  2. Investor Presentation Feb 2026
  3. Investor Presentation Feb 2026
  4. Result Nov 2025
  5. Annual Report May 2024

Alkem Laboratories FAQ

Alkem Laboratories today is trading in the green, up by 0.68% at ₹5,113.5.
Alkem Laboratories is currently trading up 0.68% on an intraday basis. In the past week the stock rose 3.37%. Stock has been down 12.09% in the past quarter and fell 7.45% in the past year. You can view this in the share price history/seasonality section.
Alkem Laboratories is listed on NSE with the ticker ALKEM and on BSE as 539523. It's currently trading on NSE at a share price of ₹5,113.5 and on BSE with a share price of ₹5,125.
The market cap of Alkem Laboratories is ₹61,139.56 Cr. as of Oct 30, 2026.
Alkem Laboratories announced a FINAL dividend of 500% which equals ₹10 in Aug 07, 2026.The last three ex-dates for Alkem Laboratories were Feb 20, 2026, Aug 08, 2025 and Feb 14, 2025. To view the full dividend history of Alkem Laboratories click here.
Alkem Laboratories has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Alkem Laboratories reported ₹3,892.9 Cr. in revenue, ₹519.96 Cr. in net profit, and ₹918.8 Cr. in EBITD as of Aug 14, 2026 for Q1 FY26-27.
According to the predictions of 20 analysts, the share price prediction for Alkem Laboratories is ₹6,002.55 with an upside of 17%.
The PE ratio of Alkem Laboratories is 28.34 as of Oct 30, 2026.
The PB ratio of Alkem Laboratories is 4.26 as of Oct 30, 2026.
You can view the latest analyst reports on the Alkem Laboratories reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×